ARA-290

ARA-290, called cibinetide in later publications, is an attempt to split erythropoietin into its two faces. The complete hormone stimulates blood formation and protects tissue at the same time; ARA-290 reproduces only the second part. It is a synthetic peptide of eleven amino acids that mimics the water-facing side of helix B of the EPO molecule, which is exactly the segment the literature holds responsible for the cell-protective properties.

The key lies in the receptor. Blood formation runs through a homodimer of two EPO receptors. Alongside it exists a second receptor type, the innate repair receptor (IRR), assembled from one EPO receptor and CD131, the beta chain shared by several cytokine receptors. This receptor is upregulated after injury, mediates cell protection and dampens inflammation, but does not raise red cell counts. ARA-290 addresses it exclusively.

What is on record:

• Animal models: Protection in models of stroke and kidney ischemia without stimulating erythropoiesis; less cell death after ischemia; muted inflammatory cascades; data on neuropathic pain, diabetic neuropathy and wound healing. Hematocrit does not rise.
• Human pilot study: 22 sarcoidosis patients with small fiber neuropathy received intravenous doses for four weeks; the symptom score improved more than under placebo, and no safety concerns emerged.
• Phase 2b: 64 participants over 28 days; in the 4 mg group the area of corneal nerve fibers increased significantly versus placebo, while the 1 mg and 8 mg groups showed no such change.

Clinical work on diabetic neuropathy adds to this. For a research peptide, the level of maturity is unusually high.

The literature describes ARA-290 as well tolerated. The most important safety aspect is also the design idea: because only the innate repair receptor is engaged, the EPO-typical thrombosis risk from a rising hematocrit does not arise.

• Injection site: Redness, pressure or a brief irritation are the most commonly named reactions.
• General: Isolated participants report a feeling of warmth or slight fatigue shortly after dosing.
• Hematocrit: It stays unchanged in animal models; in the available data, thromboembolic risks are therefore markedly lower than with the complete hormone.
• Long-term data: The clinical trials concern neuropathy indications and limited time spans. Robust data on long-term use outside such protocols are lacking; the picture rests on trial results and animal models.

This summary is no substitute for medical advice.

• Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin - introduces the eleven-residue helix B peptide and shows tissue protection in stroke and kidney ischemia models with no effect on blood formation.
• The receptor that tames the innate immune response - explains the tissue-protective receptor built from the EPO receptor and CD131 and how it differs from the hematopoietic receptor.
• Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain - phase 2b trial with 64 participants in which only the 4 mg group showed more corneal nerve fibers.